Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
ConditionHormone Therapy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorUniversity of Calgary
About this trial
1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women. 2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.
Eligibility criteria
Qualifiers
Age 18 to 90 years
Taking hormones orally or non-orally (either estrogen, progesterone or testosterone)
Disqualifiers
Cardiovascular disease (symptoms consistent with myocardial ischemia, previously documented myocardial ischemia, cardiac arrhythmias or valve abnormalities, or abnormal ECG at screening)
Cerebrovascular disease (transient ischemic attacks or stroke)
History of hypertension (BP>140/90 or use of antihypertensive medications)
Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2
Trial design
Treatments tested in this trial
- Captopril Tablets
- Iohexol
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov